Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients

Απλή σελίδα τεκμηρίου
dc.contributor.authorPectasides, D.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorGogou, L.en
dc.contributor.authorAntoniou, F.en
dc.contributor.authorNicolaides, C.en
dc.contributor.authorTsikalakis, D.en
dc.date.accessioned2015-11-24T19:30:15Z
dc.date.available2015-11-24T19:30:15Z
dc.identifier.issn0277-3732-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23051
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntigens, Neoplasm/blooden
dc.subject*Antigens, Tumor-Associated, Carbohydrateen
dc.subjectBreast Neoplasms/*diagnosis/mortality/pathologyen
dc.subjectCarcinoembryonic Antigen/blooden
dc.subjectCarcinoma/*diagnosis/mortality/pathology/secondaryen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMiddle Ageden
dc.subjectMucin-1/blooden
dc.subjectPredictive Value of Testsen
dc.subjectSensitivity and Specificityen
dc.subjectSurvival Rateen
dc.subjectTissue Polypeptide Antigen/blooden
dc.subjectTumor Markers, Biological/*blooden
dc.titleClinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patientsen
heal.abstractA total of 209 postsurgical breast cancer patients were prospectively monitored with simultaneous serum level estimations of CA 15,3, mucin-like carcinoma-associated antigen (MCA), tumor polypeptide antigen (TPA), and carcinoembryonic antigen (CEA); 141 (67.5%) were free of recurrence and 68 (32.5%) developed metastases during the follow-up. The mean values of tested tumor markers differed significantly in those with progressive disease compared with those free of disease recurrence. The sensitivity of tumor markers were CA 15-3, 68.2%; CEA, 34.1%; MCA, 72.7%; and TPA, 72.7%. The combination of CA 15-3 with TPA or MCA with TPA showed a trend for improved sensitivity of both markers (p = 0.06), with no specific loss of specificity (p = 0.11). The addition of CEA to CA 15-3 or MCA does not provide additional information for clinical evaluation. Patients with elevated tumor marker determinations had significantly shorter survival than those with values within the normal range. Two serial, progressively increasing values of tumor markers during the follow-up strongly predict recurrence. This study indicates that the comeasurement of CA 15-3 with TPA or MCA with TPA is justifiable in monitoring breast cancer patients postoperatively.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/8823487-
heal.journalNameAm J Clin Oncolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1996-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ